Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-1 antitrypsin (AAT) is a serine protease inhibitor primarily produced in the liver. Its main function is to protect tissues, especially in the lungs, from damage by proteolytic enzymes such as neutrophil elastase. Deficiency in AAT leads to unopposed activity of neutrophil elastase, resulting in tissue damage and diseases such as emphysema and liver cirrhosis.
Inhibits neutrophil elastase and other serine proteases by forming a stable complex, preventing tissue degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-1 antitrypsin (AAT).